Table of Contents

• Trial overview
• Who is being studied
• Trial phases and study designs
• Main outcomes being measured
• How Zimberelimab is being tested
• Rare cancers and special patient groups
• Safety and tolerability in the trials

Trial overview

The trial data shows that Zimberelimab is being studied in many cancer types, often with other drugs such as domvanalimab, chemotherapy, or sacituzumab govitecan.^[1] These studies look at whether the treatment helps people live longer, stay free of cancer growth, or have a tumor response.^[1]

The included studies cover both common cancers and rare cancers, and they use different research designs such as single-arm studies and randomized comparisons.^[1][2]

Who is being studied

Many trials include adults with advanced or metastatic cancer, which means the cancer is widespread or has spread to other parts of the body.^[1] Some studies focus on people whose cancer got worse after standard treatment, while others enroll people who have not yet received treatment.^[1][2]

Some trials are for people with disease that can still be removed with surgery, such as resectable non-small cell lung cancer and muscle-invasive bladder cancer.^{[3][4] Other trials focus on harder-to-treat groups, such as people with rare cancers or cancers that returned after earlier therapy.[5][6]}

Trial phases and study designs

The source data includes Phase 1, Phase 2, and Phase 3 trials.^[1] Phase 1 studies are usually early studies that focus on safety, while Phase 2 studies check for early benefit and continue safety testing.^[7] Phase 3 studies are larger and compare treatment strategies more directly.^[8]

Several studies are randomized, which means participants are assigned to different treatment groups by chance.^{[8][9] Some are open-label, which means both the study team and the participant know what treatment is being given.[10]}

Main outcomes being measured

A common endpoint is overall survival (OS), which measures how long patients live after randomization.^{[8][9] Other trials measure progression-free survival (PFS), which is the time before the cancer gets worse or the patient dies.[2][7]}

Some studies use objective response rate (ORR), meaning the percentage of patients whose cancer shrinks or disappears on scans using RECIST 1.1 criteria, a standard way to measure tumor size changes.^{[2][2] Surgery-based trials may measure pathologic complete response (pCR), which means no viable tumor cells are found in the removed tissue.[3][4]}

Other endpoints include event-free survival (EFS) and disease-free survival (DFS), which both focus on how long patients remain without a major cancer event or recurrence after treatment.^[3][11]

How Zimberelimab is being tested

In several studies, Zimberelimab is combined with domvanalimab and chemotherapy to see whether this combination improves outcomes compared with another treatment plan.^{[8][9] For example, one phase 3 lung cancer study compares domvanalimab plus Zimberelimab with pembrolizumab, both with chemotherapy.[8]}

Other studies test Zimberelimab with sacituzumab govitecan in bladder cancer and non-small cell lung cancer, including before surgery and after surgery.^{[3][4] There is also a phase 1 colorectal cancer study that looks at Zimberelimab in combination regimens and tracks both efficacy and treatment-emergent adverse events.[7]}

Rare cancers and special patient groups

One important study, IMMUNORARE5, is a phase 2 platform trial for adults with five rare advanced cancers: peritoneal mesothelioma, gestational trophoblastic tumors, thymic tumors, anaplastic thyroid carcinoma, and gastroenteropancreatic or unknown-origin neuroendocrine tumors.^[5] These patients must have progressive or resistant disease after at least one standard systemic treatment.^[5]

Another study focuses on people with PD-L1 positive advanced triple-negative breast cancer, which is a breast cancer subtype with a specific test result called PD-L1 positivity.^[6] The trial studies first-line treatment, meaning treatment given as the first cancer therapy for that disease setting.^[6]

Safety and tolerability in the trials

Some trials specifically measure adverse events, serious adverse events, and other safety trends, showing that safety remains an important part of the research program.^{[10][12] In these studies, researchers want to know not only whether the treatment works, but also how well patients tolerate the treatment combinations over time.[10][12]}

Because the studies are in different cancer types and different lines of treatment, the main goal is not one single result, but a set of cancer-specific outcomes that fit each patient group.^[1][5]